ICU Medical (NASDAQ: ICUI) insider transactions

In the twelve months to 10 November 2026, executives and directors of ICU Medical reported 19 open-market sales of 49,624 shares ($8.3m) and 0 open-market purchases, by 7 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in ICU Medical shares reported on Form 4
Date	Insider	Role	Transaction	Shares	Price	Held after	Filing
3 September 2026	Sanzone Virginia Ruth	VP, General Counsel	Open-market sale, 10b5-1 plan	−2,202	$167.67	17,258	Form 4
3 September 2026	Sanzone Virginia Ruth	VP, General Counsel	Open-market sale, 10b5-1 plan	−1,238	$168.44	16,020	Form 4
3 September 2026	Sanzone Virginia Ruth	VP, General Counsel	Open-market sale, 10b5-1 plan	−724	$169.53	15,296	Form 4
3 September 2026	Sanzone Virginia Ruth	VP, General Counsel	Open-market sale, 10b5-1 plan	−692	$171.52	14,604	Form 4
1 September 2026	Bonnell Brian Michael	Chief Financial Officer	Open-market sale, 10b5-1 plan	−6,381	$175.00	56,062	Form 4
31 August 2026	Bonnell Brian Michael	Chief Financial Officer	Open-market sale, 10b5-1 plan	−1,712	$171.05	70,038	Form 4
31 August 2026	Bonnell Brian Michael	Chief Financial Officer	Open-market sale, 10b5-1 plan	−1,914	$172.12	68,124	Form 4
31 August 2026	Bonnell Brian Michael	Chief Financial Officer	Open-market sale, 10b5-1 plan	−4,568	$173.44	63,556	Form 4
31 August 2026	Bonnell Brian Michael	Chief Financial Officer	Open-market sale, 10b5-1 plan	−1,113	$173.91	62,443	Form 4
13 August 2026	Woolson Daniel	VP, GM-Infusion Capital	Open-market sale	−5,417	$181.33	17,062	Form 4
12 August 2026	Sousa Ben	Chief Information Officer	Open-market sale	−2,250	$178.32	3,076	Form 4
11 August 2026	Finney Elisha W	Director	Open-market sale	−378	$182.48	4,871	Form 4
11 August 2026	Voigtlander Christian B.	Chief Operating Officer	Open-market sale	−8,929	$182.93	37,377	Form 4
22 May 2026	Woolson Daniel	President	Open-market sale	−2,123	$132.21	22,479	Form 4
14 May 2026	Sanzone Virginia Ruth	VP, General Counsel	Open-market sale	−2,447	$124.08	19,460	Form 4
13 May 2026	Finney Elisha W	Director	Option exercise	+1,254	—	5,249	Form 4
13 May 2026	Hoffmeister David F	Director	Option exercise	+1,254	—	6,004	Form 4
13 May 2026	Kennedy Kolleen T	Director	Option exercise	+1,254	—	4,539	Form 4
13 May 2026	Abbey Donald	Director	Option exercise	+1,254	—	6,004	Form 4
13 May 2026	Greenberg David C.	Director	Option exercise	+1,254	—	9,214	Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the ICU Medical page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.